Objective: Comparing the efficacy of Vaccinium arctostaphylos leaf and fruit extracts with placebo in the treatment of hypertensive hyperlipidemic type 2 diabetic patients. Study design: randomized, double-blind, placebo-controlled, three group parallel design, single-center, phase 2 of clinical trial. Study population: Hypertensive hyperlipidemic type 2 diabetic patients. Sample size: 150 patients. Inclusion criteria: Iranian male and female hypertensive hyperlipidemic type 2 diabetic outpatients; patients aged 40 to 60 years; patients with blood HbA1c levels between 7% and 9%; patients with fasting blood LDL levels between 100 mg/dL and 150 mg/dL; patients with systolic blood pressures between 14 and 16 mmHg; patients with diastolic blood pressures between 9 and 10 mmHg; patients taking 15 mg glibenclamide, 2 g metformin and 20 mg atorvastatin per day; patients taking synthetic antihypertensive drugs with 3 different mechanisms per day. Exclusion criteria: Patients taking other drugs effective on the blood glucose and lipid levels; patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, tachycardia, vertigo and seizure; patients with a history of gallstones or gall bladder surgery; pregnant women;women planning pregnancy; breast-feeding women. Interventions: Each of the Vaccinium arctostaphylos leaf and fruit extracts are administered separately to a group of 50 patients at the dose of one 350 mg capsule every 8 hours for 2 months and one placebo capsule is administered to another group of 50 patients every 8 hours for 2 months. Before intervention and 2 months after intervention, the primary and secondary outcome variables are evaluated. Primary outcome variables: Blood levels of glycosylated hemoglobin and LDL-C and amounts of systolic and diastolic blood pressures. Secondary outcome variables: Blood levels of fasting glucose, 2 hour postprandial glucose, total cholesterol, triglyceride, HDL-C, creatinine, SGOT and SGPT.